Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Intraosseous Injection of Flurbiprofen Axetil for Postoperative Analgesia in Joint Arthroplasty

18. november 2026 opdateret af: Hua Luo, Taizhou Hospital

This single-center, prospective, randomized, double-blind, double-dummy controlled trial aims to evaluate the efficacy and safety of intraosseous versus intravenous flurbiprofen axetil for postoperative pain management in patients undergoing joint arthroplasty.

A total of 240 patients aged 65-80 years undergoing primary unilateral total knee arthroplasty, unicompartmental knee arthroplasty, total hip arthroplasty, or hemiarthroplasty will be enrolled. Participants will be stratified according to surgical procedure and randomly assigned in a 1:1 ratio to receive either intraosseous flurbiprofen axetil with intravenous saline placebo or intravenous flurbiprofen axetil with intraosseous saline placebo. The dose of flurbiprofen axetil will be 50 mg in both groups.

The primary outcome is postoperative pain intensity at rest, assessed using the Visual Analog Scale (VAS) at predefined time points from 1 hour to 6 weeks after surgery. Secondary outcomes include pain during movement, cumulative opioid consumption within 72 hours, length of hospital stay, joint functional recovery, patient satisfaction, patient-controlled analgesia utilization, and adverse events.

This study aims to determine whether intraosseous administration of flurbiprofen axetil provides effective and safe postoperative analgesia compared with conventional intravenous administration following joint arthroplasty.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

240

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • Zhejiang
      • Linhai, Zhejiang, Kina, 317000
        • Rekruttering
        • No. 150 Ximen Road
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

65 år til 80 år (Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Adults aged 65 to 80 years, regardless of sex.
  • Patients scheduled to undergo unilateral joint arthroplasty.
  • Patients scheduled for elective surgery with standardized surgical procedures and prosthesis types, consistent with the postoperative analgesia protocol of this study.
  • Patients scheduled to receive general anesthesia.
  • Patients who are able to understand the study objectives, procedures, and potential risks, voluntarily provide written informed consent, and cooperate with postoperative assessments, including Visual Analog Scale (VAS) pain scores, functional assessments, and patient satisfaction evaluations.

Exclusion Criteria:

  • Known hypersensitivity to flurbiprofen, other nonsteroidal anti-inflammatory drugs (NSAIDs), or contraindications to opioids or other medications used in the study.
  • Contraindications to NSAID use, including peptic ulcer disease, gastrointestinal bleeding, severe hepatic or renal impairment, or coagulation disorders.
  • Severe cardiovascular, hepatic, renal, hematological, or central nervous system diseases that may prevent patients from tolerating general anesthesia or analgesic medications.
  • Recent history of gastrointestinal bleeding or active peptic ulcer disease.
  • Severe infection, immunodeficiency, or risk of sepsis.
  • Psychiatric disorders or cognitive impairment that prevent reliable assessment of postoperative pain intensity or patient satisfaction.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Dobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Intraosseous Flurbiprofen

Participants will receive a total dose of 50 mg flurbiprofen axetil via intraosseous administration.

For knee arthroplasty, the medication will be administered into the distal femoral and proximal tibial bone cavities. For hip arthroplasty, the medication will be administered into the bone cavity near the greater trochanter.

Flurbiprofen axetil 50 mg will be administered intraosseously into the distal femoral and proximal tibial bone cavities for knee arthroplasty or near the greater trochanter for hip arthroplasty.

Flurbiprofen axetil 50 mg will be administered intravenously.

Aktiv komparator: Intravenous Flurbiprofen Axetil

Participants will receive 50 mg flurbiprofen axetil through intravenous administration.

Flurbiprofen axetil 50 mg will be administered intraosseously into the distal femoral and proximal tibial bone cavities for knee arthroplasty or near the greater trochanter for hip arthroplasty.

Flurbiprofen axetil 50 mg will be administered intravenously.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Visual Analog Scale
Tidsramme: At 1, 2, 3, 4, 5, 6, 12, 24, 48, and 72 hours after surgery; postoperative day 7; and postoperative weeks 2 and 6.

Postoperative pain intensity at rest will be assessed using the Visual Analog Scale (VAS), ranging from 0 (no pain) to 10 (worst imaginable pain). Higher scores indicate greater pain intensity.

At 1, 2, 3, 4, 5, 6, 12, 24, 48, and 72 hours after surgery; postoperative day 7; and postoperative weeks 2 and 6.

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Cumulative Opioid Consumption Within 72 Hours
Tidsramme: up to 72 hours post-surgery

The cumulative dose of opioid analgesics administered during the first 72 hours after surgery will be recorded. Opioid consumption will be converted into morphine milligram equivalents to facilitate comparison between the two treatment groups.

up to 72 hours post-surgery
Length of Hospital Stay
Tidsramme: From the date of hospital admission to the date of hospital discharge, assessed up to 30 days.

The length of hospital stay will be calculated as the number of days from hospital admission to hospital discharge. The duration of hospitalization will be compared between the two treatment groups. Unit: days.

From the date of hospital admission to the date of hospital discharge, assessed up to 30 days.
Knee Society Score
Tidsramme: At baseline (preoperative assessment), postoperative days 1, 3, and 7, and postoperative weeks 2 and 6.

Postoperative knee function will be evaluated using the Knee Society Score (KSS). Scores are recorded at predefined postoperative time points and compared between the two treatment groups to assess functional recovery. Unit: score.

At baseline (preoperative assessment), postoperative days 1, 3, and 7, and postoperative weeks 2 and 6.
Patient Satisfaction With Postoperative Analgesia
Tidsramme: At hospital discharge.

Patient satisfaction with postoperative analgesia will be assessed using a 10-point Numerical Rating Scale (NRS), ranging from 0 (completely dissatisfied) to 10 (completely satisfied). Higher scores indicate greater satisfaction. Unit: score.

At hospital discharge.
Cumulative PCA Analgesic Consumption
Tidsramme: From PCA initiation to PCA discontinuation, within the first 72 hours after surgery.

The cumulative amount of analgesic medication delivered through the patient-controlled analgesia (PCA) system will be recorded from PCA initiation until discontinuation. The total medication consumption will be expressed in milligrams (mg), and the duration of PCA use will also be recorded. Unit: mg.

From PCA initiation to PCA discontinuation, within the first 72 hours after surgery.
Incidence of Adverse Events
Tidsramme: up to 3 months post-surgery

The incidence of adverse events will be assessed in both treatment groups. Recorded events will include gastrointestinal bleeding, renal impairment, cardiovascular events, and wound infection ect.

up to 3 months post-surgery

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

31. december 2025

Primær færdiggørelse (Faktiske)

1. april 2026

Studieafslutning (Anslået)

30. april 2027

Datoer for studieregistrering

Først indsendt

23. oktober 2026

Først indsendt, der opfyldte QC-kriterier

18. november 2026

Først opslået (Faktiske)

20. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

20. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

18. november 2026

Sidst verificeret

1. oktober 2026

Mere information

Begreber relateret til denne undersøgelse

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • K20251066

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .